Esophageal cancer exhibits resistance to a novel IGF-1R inhibitor NVP-AEW541 with maintained RAS-MAPK activity.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Anticancer Research

• Publication date

  2012-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 22753744
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• KRAS and BRAF Mutations Predict Primary Resistance to Imatinib in Gastrointestinal Stromal Tumors

  2012cited by this paper
• Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule 111In-DOTA-ZIGF1R:4551

  2012cited by this paper
• RAS oncogenes: weaving a tumorigenic web

  2011cited by this paper
• R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study.

  2011cited by this paper
• Identification of Signature Genes for Detecting Hedgehog Pathway Activation in Esophageal Cancer

  2011cited by this paper
• Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures

  2011cited by this paper
• The metabolic regulator ERRα, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer.

  2011cited by this paper
• The IGF system

  2011cited by this paper
• Molecular Target Characterization and Antimyeloma Activity of the Novel, Insulin-like Growth Factor 1 Receptor Inhibitor, GTx-134

  2011cited by this paper
• Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model.

  2010cited by this paper
• Activating KRAS Mutations and Overexpression of Epidermal Growth Factor Receptor as Independent Predictors in Metastatic Colorectal Cancer Patients Treated With Cetuximab

  2010cited by this paper
• Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.

  2010cited by this paper
• Ras-induced resistance to lapatinib is overcome by MEK inhibition.

  2010cited by this paper
• Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer.

  2010cited by this paper
• Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy.

  2009cited by this paper
• Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach.

  2009cited by this paper
• Inhibition of Insulin-Like Growth Factor 1 Receptor by CP-751,871 Radiosensitizes Non–Small Cell Lung Cancer Cells

  2009cited by this paper
• Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis

  2009cited by this paper
• The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.

  2009cited by this paper
• Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis.

  2008cited by this paper
• Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.

  2008cited by this paper
• Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors

  2008cited by this paper
• siRNA mediated the type 1 insulin-like growth factor receptor and epidermal growth factor receptor silencing induces chemosensitization of liver cancer cells

  2008cited by this paper
• Overexpression of IGF-I receptor in HeLa cells enhances in vivo radioresponse.

  2007cited by this paper
• RasGRP1 overexpression in the epidermis of transgenic mice contributes to tumor progression during multistage skin carcinogenesis.

  2007cited by this paper
• AKT/PKB signaling: navigating downstream.

  2007cited by this paper
• Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

  2007cited by this paper
• Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma.

  2006cited by this paper
• Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.

  2006cited by this paper
• The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours.

  2006cited by this paper
• Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo.

  2005cited by this paper
• Type I insulin-like growth factor receptor as a therapeutic target in cancer.

  2005cited by this paper
• In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase.

  2004cited by this paper
• Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma

  2004cited by this paper
• Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer.

  2003cited by this paper
• Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases

  2002cited by this paper
• Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines.

  2002cited by this paper
• Activation of c-K-ras mutations in human gastrointestinal tumors.

  2000cited by this paper
• The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants.

  1997cited by this paper

• Identification of COL3A1, PLAU, and SPP1 as Key Biomarkers for Early Detection of Esophageal Cancer

  2025cites this paper
• Global trends in esophageal cancer and metabolic syndrome research: bibliometric analysis and visualization from 1995 to 2024

  2025cites this paper
• Tumor Suppression or Oncogenic Role of miR-100 in Cancer; Implications for Esophageal Cancer

  2018cites this paper
• Hepatocyte growth factor-induced mesenchymal-epithelial transition factor activation leads to insulin-like growth factor 1 receptor inhibitor unresponsiveness in gastric cancer cells

  2018cites this paper
• Kinase inhibitors of the IGF-1R as a potential therapeutic agent for rheumatoid arthritis

  2017cites this paper
• Overcoming Linsitinib intrinsic resistance through inhibition of nuclear factor‐κB signaling in esophageal squamous cell carcinoma

  2017cites this paper
• Discoidin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cells

  2017cites this paper
• Identification of a lncRNA involved functional module for esophageal cancer subtypes.

  2016cites this paper
• Type I insulin-like growth factor receptor signaling in hematological malignancies

  2016cites this paper
• The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link

  2015cites this paper
• IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma

  2015cites this paper
• The effect of IGF-I receptor blockade for human esophageal squamous cell carcinoma and adenocarcinoma

  2014cites this paper
• Can we unlock the potential of IGF-1R inhibition in cancer therapy?

  2014cites this paper
• PI3K-AKT-mTOR-Signaling and beyond: the Complex Network in Gastroenteropancreatic Neuroendocrine Neoplasms

  2014cites this paper
• The insulin-like growth factor-I receptor inhibitor picropodophyllin-induced selective apoptosis of hepatocellular carcinoma cell through a caspase-dependent mitochondrial pathway.

  2014cites this paper
• Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors.

  2013cites this paper
• [Roles of targeting Ras/Raf/MEK/ERK signaling pathways in the treatment of esophageal carcinoma].

  2013influential citation
• Expression of KIAA0101 protein is associated with poor survival of esophageal cancer patients and resistance to cisplatin treatment in vitro

  2013cites this paper